INTRODUCTION
Venous thromboembolism (VTE), which contains deep vein thrombosis (DVT) and pulmonary embolism (PE), is not an uncommon medical problem [1] . The reported age standardized incidence of first time VTE was 1.92 per 1,000 person-years in the United States [2] . In Korea, the incidence of DVT was 5.31 per 100,000 in 2008 and is increasing with time [3] . VTE is a significant cause for morbidity and mortality in the general population, the socioeconomic burden due to VTE is substantial [4] . Especially, iliofemoral DVT accounts for 20-25% of lower limb DVT and has the highest risk for post thrombotic syndrome (PTS) and post phlebitic syndrome [5] . Thus, patients with
The results of aspiration thrombecomy iliofemoral DVT are more prone to lifelong complications.
Systemic anticoagulation therapy is a classic treatment modality for VTE. However, it does not actively dissolve thrombus and has no effect on PTS prevention [6] . Therefore, the various methods for effective thrombus removal that reduce complications such as post thrombotic morbidity have been introduced [5, 7] .
Catheter directed thrombolysis (CDT) for iliofemoral DVT was presented in the early 1990s as an alternative to anticoagulation, systemic thrombolysis, or surgical thrombectomy [8] [9] [10] [11] . CDT is an image-guided technique involving infusion of thrombolytic agents through a multiside hole infusion catheter or wire placed directly into a venous thrombus through a remote puncture site [12] . The main purpose of CDT is to restore the venous lumen and preserve the function of venous valves [13] . CDT improved long-term outcome after iliofemoral DVT by reducing PTS compared with conventional treatment with anticoagulation [14] . But the results of published studies demonstrated that the patients who underwent CDT needed long hospitalization and intensive care monitoring. And CDT therapy has a risk of hemorrhage, particularly in elderly patients [15] . Thus, CDT therapy may be used for patients with extensive acute proximal DVT (iliofemoral DVT, symptoms for ≤14 days, good functional status, life expectancy ＞1 year) who have a low risk of bleeding (grade 2B) according to the latest American College of Chest Physicians guidelines [16] .
Manual aspiration thrombectomy (AT) was first reported in 1984 [17] . AT restores venous patency and relieves acute symptoms quickly as well as reduces the risk of hemorrhagic complication [18] . But AT also has several defects such as incomplete thrombus removal, the potential for vein or valve injury and embolization risks [19] .
This study was conducted to evaluate the results of AT in the endovascular treatment for iliofemoral DVT through a comparison of CDT-alone group and CDT with AT group, including the amount of thrombolytic agent, procedure duration, completion of thrombus removal, symptom resolve, patency rate, etc. Exclusion criteria were iliofemoral DVT more than 14 days from symptom onset, patients who could not use urokinase and anticoagulation, terminally ill patients, and the presence of PE. End-points of study were recurrent symptomatic venous thrombosis, development of PE, major hemorrhage needing transfusion, and death. All patients were followed up every 6 months and duplex scans or 3D venous CT were checked.
METHODS
In prone position on the angiographic table, the venography was done and the topography of the thrombus was established. After local anesthesia, an infusion catheter was introduced under ultrasonographic guidance, preferentially into the popliteal vein. A multiside hole catheter was located across the thrombosed venous segment and attached to a low dose infusion of a thrombolytic drug.
Urokinase was used as the thrombolytic agent in all cases.
Urokinase was given in a loading dose of 120,000-250,000 IU/hr for 2 hours followed by infusion of 30,000-60,000 IU/hr for 22 hours through the main route of catheter; the rate used depended on the patient's condition, amount of thrombus, and the patient's weight. Heparin was ad- Values are presented as mean ± standard deviation. CDT, catheter directed thrombolysis; AT, aspiration thrombectomy. Values are presented as mean ± standard deviation. CDT, catheter directed thrombolysis; AT, aspiration thrombectomy. was used to compare the mean differences between the two groups. We compared the frequency of complete thrombus removal using chi-square. Symptom resolution was estimated by using the Fisher's exact test. Stent patency was estimated by using the Kaplan-Meier method and comparisons of patency were made with the log rank test. A P-value ＜ 0.05 was considered to be statistically significant.
RESULTS

Demographic information of the patients is presented
in As shown in Table 2 , the mean procedural time of the CDT-alone group was longer than the CDT with AT group Values are presented as number (%). CDT, catheter directed thrombolysis; AT, aspiration thrombectomy. There were three patients with minor wound hematoma in all groups. No surgical interventions were required for these hemorrhagic complications. There was no complication related to AT or thrombolytic catheter itself.
PE was not noted in all groups at arterial phase of 3D venous CT. There was no major morbidity or mortality. compared to CDT-alone group coincided with our data. In addition, CDT with AT was associated with a reduction in the cost of interventional material and the number of venographic assessments in the interventional suites [21] . AT is also associated with shorter intensive care unit and hospital stays as well as reduced hospital costs without difference of thrombus removal rate between CDT with AT and CDT alone [20] . We did not check the hospital costs.
Because the procedure time and the amount of thrombolytic agents were decreased, medical costs might be reduced.
There were no statistically significant differences in clinical outcomes judged by complete thrombus removal and elimination of symptom between the two groups. But, the frequency of complete thrombus removal was higher in CDT with AT group (67.6%) than CDT-only group (51.7%). The frequency of symptom resolution was also higher in CDT with AT group (85.9%) than CDT-only group (82.8%).
With mechanical clot dissolution, clot migration or embolization is of clinical concern. The incidence of symptomatic PE and fatal PE during CDT was reported as 1% and 0% to 0.2%, respectively [12, 22] . Kinney et al. [23] reported that CDT with AT had a higher rate of PE complications when used for hemodialysis graft declotting but not when used for DVT treatment. Cases of PE were not noted in each group in our series, but entrapped thrombus during procedure was noted in 6 of 37 cases in the CDT with AT group and 0 of 9 cases in the CDT-alone group among 46 patients previously inserted with prophylactic IVC filter.
Noguchi et al. [24] reported that temporary IVC filters are useful and safe for the management of an acute proximal DVT, especially in patients who require aggressive thrombus removal. When we viewed the above results, prophylactic IVC filter insertion should be considered for the prevention of PE by floating thrombus in AT treatment.
In conclusion, our study suggested that the use of AT offers more effective thrombus removal in less time and doses of thrombolytic agents required. CDT with AT is safe and effective for the treatment of an acute iliofemoral DVT. In AT treatment, prophylactic IVC filter insertion should be considered for the prevention of PE by floating thrombus.
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